• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)

    2/14/22 1:57:46 PM ET
    $SIOX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SIOX alert in real time by email
    SC 13G/A 1 sioxa1_21422.htm CONSONANCE CAPITAL MANAGEMENT LP sioxa1_21422.htm
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 1)*
    SIO GENE THERAPIES INC
    (Name of Issuer)
    Common Stock, par value $0.00001 per share
    (Title of Class of Securities)
    829399104
    (CUSIP Number)
    December 31, 2021
    (Date of Event which Requires Filing of this Statement)
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    [X] Rule 13d-1(b)
    [   ] Rule 13d-1(c)
    [   ] Rule 13d-1(d)
    * The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see Instructions).
    CUSIP No.: 829399104
           
    1
    NAME OF REPORTING PERSON
    Consonance Capital Management LP
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    IA, PN
    CUSIP No.: 829399104
           
    1
    NAME OF REPORTING PERSON
    Mitchell Blutt
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    HC, IN
    CUSIP No.: 829399104
           
    1
    NAME OF REPORTING PERSON
    Consonance Capman GP LLC
    I.R.S. IDENTIFICATION NO. OF ABOVE PERSON (ENTITIES ONLY)
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (a) [   ]
    (b) [   ]
    3 SEC USE ONLY
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
    Delaware USA
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5
    SOLE VOTING POWER
    6
    SHARED VOTING POWER
    0
    7
    SOLE DISPOSITIVE POWER
    8
    SHARED DISPOSITIVE POWER
    0
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
    0
    10
    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES
    [   ]
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
    0
    12
    TYPE OF REPORTING PERSON
    HC, OO
    CUSIP No.: 829399104
    ITEM 1(a). NAME OF ISSUER:
    SIO GENE THERAPIES INC
    ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
    130 West 42nd Street, 28th Floor, New York, NY 10036
    ITEM 2(a). NAME OF PERSON FILING:
    Consonance Capital Management LP
    Mitchell Blutt
    Consonance Capman GP LLC
    ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
    1370 Avenue of the Americas
    Floor 33
    New York, NY 10019
    ITEM 2(c). CITIZENSHIP:
    Consonance Capital Management LP - Delaware USA
    Mitchell Blutt - USA
    Consonance Capman GP LLC - Delaware USA
    ITEM 2(d). TITLE OF CLASS OF SECURITIES:
    Common Stock, par value $0.00001 per share
    ITEM 2(e). CUSIP NUMBER:
    829399104
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO SECTION 240.13d-1(b), or 13d-2(b) or (c) CHECK WHETHER THE PERSON FILING IS A:
    (a)
    [ ]
    Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78c);
    (b)
    [ ]
    Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)
    [ ]
    Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8);
    (e)
    [X]
    An investment adviser in accordance with 240.13d-1(b)(1)(ii)(E);
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with 240.13d-1(b)(1)(ii)(F);
    (g)
    [X]
    A parent holding company or control person in accordance with 240.13d-1(b)(1)(ii)(G);
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)
    [ ]
    A non-U.S. institution in accordance with 240.13d-1(b)(1)(ii)(J);
    (k)
    [ ]
    Group, in accordance with 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with 240.13d1(b)(1)(ii)(J), please specify the type of institution:
    ITEM 4. OWNERSHIP
    (a) Amount beneficially owned:
    Consonance Capital Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0

    (b) Percent of class:
    Consonance Capital Management LP - 0%
    Mitchell Blutt - 0%
    Consonance Capman GP LLC - 0%
    (c) Number of shares as to which the person has:
    (i) sole power to vote or to direct the vote:
    (ii) shared power to vote or to direct the vote:
    Consonance Capital Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0
    (iii) sole power to dispose or direct the disposition of:
    (iv) shared power to dispose or to direct the disposition of:
    Consonance Capital Management LP - 0
    Mitchell Blutt - 0
    Consonance Capman GP LLC - 0

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [X].
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON:
    The ownership information in Item 4 is incorporated herein by reference.
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY:
    Not applicable.
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP:
    Not applicable.
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP:
    Not applicable.
    ITEM 10. CERTIFICATION:
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
    CUSIP No.: 829399104
    SIGNATURE
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
    February 14 2022
    Consonance Capital Management LP
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 14 2022
    Mitchell Blutt
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    February 14 2022
    Consonance Capman GP LLC
    By:
    /s/ Mitchell Blutt
    Name:
    Mitchell Blutt
    Title:
    Manager & Member
    Attention — Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001).
    CUSIP No.: 829399104
    Item 4. Ownership:
    This amendment is submitted to report that as of December 31, 2021, none of Consonance Capital Master Account LP (Consonance Master), Consonance Capital Opportunity Master Fund, LP (Consonance Opportunity Master), Consonance Capital Management LP, the investment adviser of Consonance Master and Consonance Opportunity Master (the Adviser), a managed account managed by the Adviser, Consonance Capman GP LLC, the general partner of the Adviser (Capman), and Mitchell Blutt, the Manager & Member of Capman and Chief Executive Officer of the Adviser, held any shares of the Issuers Common Stock.

    EXHIBIT 99.1
    JOINT FILING AGREEMENT
    In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a Statement on Schedule 13G dated February 14, 2022 (including amendments thereto) with respect to the Common Stock, par value $0.00001 per share, of SIO GENE THERAPIES INC. This Joint Filing Agreement shall be filed as an Exhibit to such Statement. The undersigned acknowledge that each shall be responsible for the timely filing of any amendments to such joint filing and for the completeness and accuracy of the information concerning him or it contained herein and therein, but shall not be responsible for the completeness and accuracy of the information concerning the others.

    CONSONANCE CAPITAL MANAGEMENT LP
    By: Consonance Capman GP LLC /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    MITCHELL BLUTT
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member

    CONSONANCE CAPMAN GP LLC
    By: /s/ Mitchell Blutt
    Name: Mitchell Blutt
    Title: Manager & Member
    Get the next $SIOX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SIOX

    DatePrice TargetRatingAnalyst
    2/1/2022$10.00 → $7.00Buy
    HC Wainwright & Co.
    2/1/2022$6.00 → $1.00Outperform → Market Perform
    SVB Leerink
    10/21/2021$8.00 → $10.00Buy
    HC Wainwright & Co.
    8/12/2021$7.00 → $6.00Outperform
    SVB Leerink
    7/12/2021$12.50Buy
    Chardan Capital Markets
    More analyst ratings

    $SIOX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Sio Gene Therapies, Inc. to File for Dissolution and Declare an Initial Liquidating Distribution of $0.435 Per Share

      PARSIPPANY, N.J., Feb. 02, 2024 (GLOBE NEWSWIRE) -- Sio Gene Therapies, Inc. ("Sio") today announced that it expects to file a certificate of dissolution (the "Certificate of Dissolution") with the Secretary of State of the State of Delaware, as contemplated by the Plan of Complete Liquidation and Dissolution (the "Plan") previously approved by Sio's Board of Directors and stockholders, on February 7, 2024. The Certificate of Dissolution, which is expected to become effective at 4:00 p.m. Eastern Time on February 7, 2024 (the "Effective Time"), provides for the dissolution of Sio under the General Corporation Law of the State of Delaware (the "DGCL"). In connection with the filing of th

      2/2/24 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Fiscal Third Quarter 2022 Financial Results

      –  Three-Month and Nine-Month Losses decline by 84.2% and 73.5%, respectively –  Operating Cash Outflows for the Nine Months Ended December 31, 2022 decreased by $23.8 million or 56% versus the prior year period –  $46.1 million of cash and cash equivalents as of December 31, 2022, a strong cash position as the Company prepares for liquidation and dissolution, subject to stockholder approval NEW YORK, Feb. 14, 2023 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today provided financial results for its fiscal third quarter ended December 31, 2022. "Our financial results continue to show the beneficial effects on operating expenses and cash burn resulting from the termination

      2/14/23 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Inc. Announces Board Approval of Plan of Complete Liquidation and Dissolution

      NEW YORK, Dec. 14, 2022 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX) today announced that its Board of Directors has determined, after extensive and careful consideration of potential strategic alternatives, that it is in the best interests of the Company and its shareholders to dissolve the Company and liquidate its assets, including its subsidiaries. "After evaluating the Company's strategic options, the Board of Directors unanimously concluded that it is in the best interests of the shareholders to dissolve and liquidate the Company," stated David Nassif, Chief Executive Officer. "The Board of Directors and management, together with its external advisors, devoted substanti

      12/14/22 4:49:43 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Meswani Parag V

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/10/22 5:07:32 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Nassif David W.

      4 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/10/22 5:05:27 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3: New insider Meswani Parag V claimed ownership of 33,733 shares

      3 - Sio Gene Therapies Inc. (0001636050) (Issuer)

      2/7/22 7:17:01 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Financials

    Live finance-specific insights

    See more
    • Sio Gene Therapies Announces Positive Interim Safety and Biomarker Data from Ongoing Phase 1/2 Clinical Study of AXO-AAV-GM1 Gene Therapy in GM1 Gangliosidosis

      Consistent dose-dependent improvements across biomarker measuresNormalization of serum beta-galactosidase activity and GM1 ganglioside in CSF in the high-dose cohort No overt disease progression in six out of seven patients treated across low- and high-dose cohorts Total of ten patients have received gene therapy to date without SAEs attributable to AXO-AAV-GM1 Management to host conference call and webcast today, October 21, at 8:30 a.m. EDT NEW YORK and DURHAM, N.C., Oct. 21, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ:SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today pres

      10/21/21 5:30:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies Announces Financial Results for Third Fiscal Quarter Ended December 31, 2020

      - Company had $81 million of cash and cash equivalents as of December 31, 2020, and expects to receive additional $16 million in cash in 2021 from sale of Arvelle Therapeutics shares - Cash runway expected into the second calendar quarter of 2022 NEW YORK and RESEARCH TRIANGLE PARK, N.C., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Sio Gene Therapies Inc. (NASDAQ: SIOX), a clinical-stage company focused on developing gene therapies to radically transform the lives of patients with neurodegenerative diseases, today provided financial results for its third fiscal quarter ended December 31, 2020. “In recent months, Sio Gene Therapies has made important progress in advancing its patient-fo

      2/9/21 7:00:00 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • HC Wainwright & Co. reiterated coverage on Sio Gene Therapies with a new price target

      HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $7.00 from $10.00 previously

      2/1/22 8:21:09 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sio Gene Therapies downgraded by SVB Leerink with a new price target

      SVB Leerink downgraded Sio Gene Therapies from Outperform to Market Perform and set a new price target of $1.00 from $6.00 previously

      2/1/22 6:26:53 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • HC Wainwright & Co. reiterated coverage on Sio Gene Therapies with a new price target

      HC Wainwright & Co. reiterated coverage of Sio Gene Therapies with a rating of Buy and set a new price target of $10.00 from $8.00 previously

      10/21/21 12:26:01 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)

      SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/13/23 8:53:10 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Sio Gene Therapies Inc.

      SC 13G - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/10/23 4:00:19 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Sio Gene Therapies Inc. (Amendment)

      SC 13G/A - Sio Gene Therapies Inc. (0001636050) (Subject)

      2/14/22 1:57:46 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SIOX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Sio Gene Therapies Inc.

      15-12G - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/25/23 4:04:47 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Sio Gene Therapies Inc.

      EFFECT - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/25/23 12:15:08 AM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form POS AM filed by Sio Gene Therapies Inc.

      POS AM - Sio Gene Therapies Inc. (0001636050) (Filer)

      4/17/23 4:15:20 PM ET
      $SIOX
      Biotechnology: Pharmaceutical Preparations
      Health Care